In this episode of MedInsights Unleashed, Professor Markus Peck-Radosavljević, MD, MBA—Professor of Medicine and Chairman of the Department of Internal Medicine & Gastroenterology at Klinikum Klagenfurt, Austria— discusses evolving treatment strategies in hepatocellular carcinoma (HCC).

The conversation explores the changing role of transarterial chemoembolization (TACE) in intermediate-stage disease, emerging clinical evidence from studies such as REPLACEMENT Emerald-1 and LEAP-012, and how new systemic and immunotherapy approaches are reshaping treatment decisions. The discussion also highlights the importance of curative opportunities, multidisciplinary care, and maintaining overall survival as the most meaningful endpoint in liver cancer treatment.